Nerandomilast significantly slowed lung function decline in patients with IPF, with the 18 mg dose showing a 68.8 mL FVC decline reduction compared with placebo. The trial included 1177 patients ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due to safety issues. The BEACON-IPF (NCT06097260) ...

The trial is currently recruiting up to 150 IPF patients to receive the therapy or placebo for ... CC-90001 is a c-Jun N-terminal kinase (JNK) inhibitor that was originally being developed by Celgene ...

While an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo groups led to the discontinuation of the trial, early evidence of efficacy on the forced vital ...

Celmatix Therapeutics (Celmatix Inc.) has announced a new drug program for endometriosis, with the development of a novel Jun-N-terminal kinase (JNK) inhibitor that targets pain and inflammation. The ...

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Bloomberg High Yield Bond ETF (Symbol: JNK) where we have ...

JNK provides exposure to high-yield junk bonds issued in the US. A high yield but faces high credit risk and refinancing risk amid current economic conditions. Despite its impressive long-term ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary fibrosis (IPF). The main end point in the study was lung function based ...

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Bloomberg High Yield Bond ETF (Symbol: JNK) where we have ...

The Initial Public Offer (IPO) had a fresh issue of up to Rs 300 crore and an offer for sale of up to 84,21,052 equity shares.

The initial public offerings (IPO) season is still in full swing and under the spotlight now is JNK India IPO and its listing date. Notably, JNK India IPO subscription was to the tune of 28.07 ...

JNK India IPO: Ahead of the listing, the shares were commanding a 31 percent premium in the grey market. JNK India stock is expected to make a decent debut on bourses on April 30. Analysts expect ...